Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 103 (12), 2468-2478

High-risk Corneal Transplantation: Recent Developments and Future Possibilities

Affiliations

High-risk Corneal Transplantation: Recent Developments and Future Possibilities

W John Armitage et al. Transplantation.

Abstract

Human corneal transplantation (keratoplasty) is typically considered to have superior short- and long-term outcomes and lower requirement for immunosuppression compared to solid organ transplants because of the inherent immune privilege and tolerogenic mechanisms associated with the anterior segment of the eye. However, in a substantial proportion of corneal transplants, the rates of acute rejection and/or graft failure are comparable to or greater than those of the commonly transplanted solid organs. Critically, while registry data and observational studies have helped to identify factors that are associated with increased risk of corneal transplant failure, the extent to which these risk factors operate through enhancing immune-mediated rejection is less clear. In this overview, we summarize a range of important recent clinical and basic insights related to high-risk corneal transplantation, the factors associated with graft failure, and the immunological basis of corneal allograft rejection. We highlight critical research areas from which continued progress is likely to drive improvements in the long-term survival of high-risk corneal transplants. These include further development and clinical testing of predictive risk scores and assays; greater use of multicenter clinical trials to optimize immunosuppressive therapy in high-risk recipients and robust clinical translation of novel, mechanistically-targeted immunomodulatory and regenerative therapies that are emerging from basic science laboratories. We also emphasize the relative lack of knowledge regarding transplant outcomes for infection-related corneal diseases that are common in the developing world and the potential for greater cross-pollination and synergy between corneal and solid organ transplant research communities.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Illustration of the structure of the healthy cornea and the configurations currently in use for full thickness (penetrating keratoplasy) and posterior and anterior partial thickness (lamellar keratoplasty) corneal allo-transplantation.
FIGURE 2.
FIGURE 2.
Representative examples of recently reported, mechanistically informed preclinical and early-phase clinical strategies for improving the outcomes for high-risk corneal allotransplants. VEGF, vascular endothelial growth factor.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Armitage WJ, Tullo AB, Larkin DF. The first successful full-thickness corneal transplant: a commentary on Eduard Zirm’s landmark paper of 1906. Br J Ophthalmol 2006901222–1223 - PMC - PubMed
    1. Zirm EK. Eine erfolgreiche totale keratoplastik (a successful total keratoplasty). 1906. Refract Corneal Surg 19895258–261 - PubMed
    1. Oliva MS, Schottman T, Gulati M. Turning the tide of corneal blindness. Indian J Ophthalmol 201260423–427 - PMC - PubMed
    1. Tan DTH, Dart JKG, Holland EJ, et al. Corneal transplantation. Lancet 20123791749–1761 - PubMed
    1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 201296614–618 - PubMed

LinkOut - more resources

Feedback